Stock listing

KRX:237690 St Pharm Co., Ltd. (에스티팜) 주가

Follow St Pharm Co., Ltd. into a list and get an email when it puts out news.

Share price · KRX:237690

₩71,600 KRW +1,400 (+2.0%)

Close on Nov 20, 2026

Past year -29.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩71,300 – ₩75,000 KRWNov 20, 2026
Volume
80,423 sharesNov 20, 2026
Market cap
₩1.34T KRWAt the close on Nov 20, 2026 · price × 18.66M shares outstanding
52-week range
₩68,900 – ₩172,100 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩12.61B KRWMedian day 88,020 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
St Pharm Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:237690 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩71,600+1,400+2.0%₩73,000₩75,000₩71,30080,423
₩70,200-800-1.1%₩71,100₩72,000₩69,40050,488
₩71,000-200-0.3%₩69,800₩72,400₩69,10053,975
₩71,200-500-0.7%₩72,600₩73,400₩70,30057,159
₩71,700-1,200-1.6%₩73,600₩75,000₩71,500113,755
₩72,900-2,100-2.8%₩74,300₩75,800₩72,00079,923
₩75,000-500-0.7%₩74,300₩76,400₩73,80084,759
₩75,500+4,000+5.6%₩72,400₩76,500₩72,200115,872
₩71,500-1,100-1.5%₩71,400₩73,800₩70,60077,697
₩72,600-1,800-2.4%₩69,400₩74,500₩69,100126,478
₩74,400+1,700+2.3%₩75,000₩78,000₩74,000156,615
₩72,700+1,300+1.8%₩71,400₩72,700₩68,900127,371
₩71,400-1,100-1.5%₩71,400₩72,200₩70,600129,680
₩72,50000.0%₩71,900₩73,700₩71,20075,970
₩72,500-1,500-2.0%₩73,100₩74,700₩71,300113,524
₩74,000-3,200-4.1%₩76,200₩77,100₩73,500118,244
₩77,200-3,200-4.0%₩80,400₩81,900₩76,200351,538
₩80,400-8,100-9.2%₩89,000₩89,900₩76,600255,946
₩88,500-1,400-1.6%₩88,400₩91,300₩88,00043,156
₩89,900+100+0.1%₩89,500₩91,200₩88,70066,573
₩89,800-3,000-3.2%₩92,700₩92,900₩88,70053,888
₩92,800+600+0.7%₩93,200₩95,800₩92,00049,045
₩92,200-2,300-2.4%₩92,700₩95,300₩91,30056,200
₩94,500+3,200+3.5%₩90,600₩94,600₩84,900102,515
₩91,300+7,500+8.9%₩83,900₩93,400₩83,900149,079
₩83,800-2,100-2.4%₩84,200₩85,200₩82,10094,716
₩85,900-100-0.1%₩85,300₩88,700₩84,60079,628
₩86,000-3,000-3.4%₩86,400₩87,300₩83,60067,422
₩89,000-3,900-4.2%₩94,200₩94,700₩88,30074,967
₩92,900-3,500-3.6%₩96,800₩96,900₩91,800101,364
₩96,400-500-0.5%₩97,600₩98,900₩95,40090,822
₩96,900+3,600+3.9%₩93,600₩99,000₩93,500154,818
₩93,300-2,300-2.4%₩95,000₩96,000₩92,40062,574
₩95,600+3,900+4.3%₩91,500₩95,800₩91,000124,179
₩91,700-1,600-1.7%₩92,900₩93,700₩91,70044,963
₩93,300+200+0.2%₩92,400₩93,500₩91,10053,516
₩93,100+1,800+2.0%₩92,800₩94,700₩92,100102,158
₩91,300+700+0.8%₩91,100₩92,800₩90,20048,558
₩90,600-400-0.4%₩92,100₩93,000₩90,50042,996
₩91,000-1,700-1.8%₩93,000₩93,300₩90,40060,228
₩92,700+800+0.9%₩93,300₩94,000₩90,600142,406
₩91,900+1,500+1.7%₩91,300₩92,200₩90,00050,063
₩90,400+900+1.0%₩89,000₩90,800₩88,10058,881
₩89,500+700+0.8%₩88,000₩91,100₩87,90064,734
₩88,800-1,200-1.3%₩88,800₩89,100₩87,40061,223
₩90,000-1,800-2.0%₩89,000₩90,400₩88,70083,248
₩91,800+800+0.9%₩90,000₩91,800₩87,700145,820
₩91,000-900-1.0%₩90,600₩91,500₩89,100146,179
₩91,900+200+0.2%₩91,800₩94,000₩91,000107,031
₩91,700-9,500-9.4%₩96,200₩96,300₩90,600370,160
₩101,200+2,200+2.2%₩99,600₩101,700₩98,80045,260
₩99,000-2,200-2.2%₩101,300₩102,300₩98,20063,258
₩101,200-1,800-1.7%₩103,000₩105,700₩100,60085,218
₩103,000-2,200-2.1%₩103,700₩105,500₩101,80076,369
₩105,200-5,000-4.5%₩108,500₩108,500₩102,000118,915
₩110,200-700-0.6%₩109,800₩112,800₩108,900166,152
₩110,900+900+0.8%₩108,600₩112,200₩108,200151,997
₩110,000+3,300+3.1%₩108,800₩112,000₩108,700165,740
₩106,700-3,500-3.2%₩106,000₩107,000₩102,500197,455
₩110,200+10,500+10.5%₩101,400₩112,000₩101,400335,571
₩99,700-11,200-10.1%₩105,500₩107,300₩97,900419,835
₩110,900+11,600+11.7%₩121,400₩121,500₩105,0001,411,054
Ticker
KRX:237690
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
KRX
Currency
KRW

What changed lately

Latest news

All St Pharm Co., Ltd. news

St Pharm Co., Ltd. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
4 in the last 12 months · 5 in all · newest Apr 27, 2026 · oldest 2025
Decks
2 decks · latest February 2023

Valuation

P/E 17.4× against a median of 28.0×: 2nd lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩1.17T KRW
P/E
17.4×
EV/sales
3.0×
EV/EBITDA
11.1×
Price/book
2.1×
Gross margin
40.2%
Operating margin
18.3%
Net margin
19.9%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
St Pharm Co., Ltd. · KRX:237690US$992.8MUS$866.1M17.4×3.0×11.1×2.1×19.9%0.0×n/a
Vcanbio Cell & Gene Engineering Corp., Ltd. Class A · SSE:600645US$1.06BUS$786.1M62.8×3.8×n/a1.9×8.2%0.0×n/a
Beijing Strong Biotechnologies Inc Class A · SZSE:300406US$1.05BUS$1.13B28.0×5.5×n/a1.9×18.2%0.3×n/a
Freenome, Inc. · NASDAQ:FRNMUS$1.04BUS$863.3M9.5×n/an/a2.2×n/a0.0×n/a
Maravai LifeSciences Holdings, Inc. · NASDAQ:MRVIUS$1.04BUS$1.11Bn/a5.2×n/a5.3×−30.8%0.8×1.56
Suzhou Novoprotein Scientific Co., Ltd. Class A · SSE:688137US$1.02BUS$909.1Mn/a38.0×n/a3.4×−60.8%0.0×n/a
Castle Biosciences, Inc. · NASDAQ:CSTLUS$1.01BUS$745.1Mn/a2.0×n/a2.1×−6.1%0.0×1.00
Guangzhou Wondfo Biotech Co., Ltd. Class A · SZSE:300482US$1.01BUS$785.0Mn/a2.7×n/a1.2×−3.2%0.0×n/a
Daan Gene Co., Ltd. Class A · SZSE:002030US$990.1MUS$810.9Mn/a7.0×n/a0.9×−95.7%0.0×n/a
Amoy Diagnostics Co., Ltd. Class A · SZSE:300685US$967.3MUS$801.3M18.8×4.4×n/a3.3×28.5%0.1×n/a
Novogene Co., Ltd. Class A · SSE:688315US$949.6MUS$685.6M43.1×2.0×n/a2.3×6.4%0.0×n/a
Median of the othersUS$1.02BUS$806.1M28.0×4.4×2.1×−3.2%0.0×1.28

Forecasts

Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
143000.00 KRW · Analysts' mean
EPS, year to Dec 2026
2415.00 · 7 analysts
Revenue, year to Dec 2026
413B · 8 analysts

Team and board

Officers

OfficerRole
Cheol-Hong KimCEO, HAON Accounting Corporation
Moo-Je SungCEO
Mooje SungPresident and CEO

Board

DirectorRole
Cheol-Hong KimCEO, HAON Accounting Corporation
Dong-Pyo KimProfessor, Department of chemical Engineering
Moo-Je SungCEO
Seung-Beom HanManaging Attorney, the Way Law Firm

Events

QuarterResultsShare move
Q1 2025Apr 30, 2025 · After close−0.1%
Q3 2024Nov 12, 2024 · After close−4.6%
Q2 2024Jul 25, 2024 · After close+5.5%
Q1 2024May 2, 2024 · After close+8.7%
Q4 2023Mar 25, 2024 · Before open+2.6%
Q3 2023Nov 14, 2023 · After close+1.4%
Q2 2023Aug 14, 2023 · After close−2.9%
Q1 2023Apr 28, 2023 · After close+13.9%
Q4 2022Feb 16, 2023 · After close−2.4%
Q3 2022Oct 31, 2022 · After close−8.6%
All 17 quarters
QuarterResultsShare move
Q2 2022Aug 8, 2022 · After close+4.2%
Q1 2022May 16, 2022 · After close+2.0%
Q4 2021Feb 24, 2022 · After close+5.0%
Q3 2021Oct 28, 2021 · Before open+2.6%
Quarter to Jun 30, 2021Jul 28, 2021 · After close+3.0%
Quarter to Mar 31, 2021Apr 28, 2021 · After close−9.9%
Quarter to Dec 31, 2020Jan 25, 2021 · After close−2.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (February 2023)Investor deck24 slidesFebruary 2023
Investor Presentation (January 2023)Investor deck26 slidesJanuary 2023

Open Decks

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue331.7B273.8B285.0B249.3B165.6B124.1B93.3B97.7B202.8B200.4B
Cost of revenue195.5B177.6B172.9B160.4B107.9B104.1B94.9B95.0B123.0B107.4B
Gross profit136.2B96.2B112.1B88.9B57.7B20.0B-1.63B2.78B79.8B93.0B
Research and development23.7B22.1B30.4B26.3B18.2B13.2B15.1B8.77B9.66B8.58B
Selling, general and administrative12.6B42.5B44.7B40.3B31.1B23.0B9.49B9.47B8.15B6.76B
Operating income54.9B27.6B33.5B17.9B5.58B-18.8B-26.7B-15.6B61.2B77.6B
Depreciation and amortization29.9B24.6B23.0B17.0B14.4B14.1B11.2B9.23B11.6B10.8B
EBITDA84.8B52.2B56.5B34.8B20.0B-4.75B-15.5B-6.42B72.7B88.3B
Interest expense4.04B7.74B6.11B2.87B5.16B644.6M0000
Income before tax58.7B42.7B23.4B19.2B1.26B-16.8B-25.0B-13.4B59.2B80.5B
Income tax-2.12B-3.67B-6.44B-4.12B14.2B19.1B
Net income55.0B34.7B19.6B18.0B3.31B-12.1B-18.5B-9.27B45.0B61.4B
Earnings per share, basic2,656.951,722.421,041.07957.00176.09-651.11-993.18-496.782,411.933,323.12

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents30.5B63.4B50.1B50.2B27.3B8.70B74.7M47.7B72.3B55.2B
Short-term investments60.4B57.5B40.0B1054.0B102.0B38.2B60.0B60.0B60.0B
Receivables96.7B67.8B120.6B94.2B62.9B45.4B35.7B15.9B31.7B13.7B
Inventory169.5B127.0B120.7B107.6B80.8B45.4B40.9B40.7B58.0B91.4B
Current assets372.7B330.1B348.4B263.2B244.1B235.6B144.2B167.3B225.2B224.9B
Property, plant and equipment338.7B280.1B257.9B210.2B175.6B171.0B169.1B151.6B138.4B
Goodwill11.8B10.6B9.95B8.95B8.46B8.04B6.69B
Total assets782.6B721.9B675.4B570.7B498.6B445.6B341.1B345.5B381.5B367.8B
Accounts payable11.8B10.6B17.7B18.1B12.9B4.69B7.16B3.09B3.11B13.7B
Current liabilities164.8B133.3B83.7B179.2B75.4B18.6B16.2B9.95B28.6B51.5B
Long-term debt43.3B159.7B16.7B91.5B125.6B15.1B97.5M117.0M136.5M
Total debt126.0B15.6B
Total liabilities189.6B218.9B288.5B233.0B175.6B150.2B40.1B13.9B30.4B54.5B
Shareholders' equity593.4B503.1B384.6B337.6B323.0B295.3B301.0B331.6B351.1B313.2B
Shares outstanding20.7M20.2M18.8M18.8M18.8M18.7M18.7M18.7M18.7M18.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations14.0B109.5B1.30B7.03B7.27B-20.9B-30.5B10.8B54.4B50.8B
Capital spending-47.3B-83.2B-43.4B-60.7B-51.8B-17.0B-6.22B-27.2B-27.7B-16.0B
Free cash flow-33.3B26.2B-42.1B-53.6B-44.6B-38.4B-36.7B-16.4B26.7B34.7B
Cash from investing-86.5B-82.4B-5.72B-8.03B-69.1B-9.77B-26.8B-26.3B-93.2B
Cash from financing-11.0B81.4B10.8B-115.6M115.9B5.32B-9.01B-9.13B85.2B
Dividends paid-10.1B-9.40B-9.40B-9.40B-9.33B-9.33B-9.24B-2.95B
Share buybacks1.15B132.2B
Change in cash-32.9B13.3B-103.9M11.0B578.2M25.8B-34.9B-24.6B17.1B43.4B

Open Financials

Cap table

Built by 6ix from St Pharm Co., Ltd.’s releases

Common shares
18,656,000
Fully diluted
18,656,000

Fully diluted

LineShares
Common shares18,656,000

Share count over time

CountShares
Nov 22, 202618,656,000

Open Cap table

Shareholders

HolderSharesValueChangeAs of
Vanguard Total International Stock Index Fund190KUS$11.7M+6,617Jul 31, 2026
iShares Core MSCI Emerging Markets ETF163KUS$14.5M+50May 31, 2026
Vanguard Developed Markets Index Fund129KUS$11M+6,472Jun 30, 2026
WCM Focused Emerging Markets Fund97,706US$8.39MNo changeJun 30, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund53,601US$3.31M+6,178Jul 31, 2026
JNL Multi-Manager Emerging Markets Equity Fund48,046US$4.12MNo changeJun 30, 2026
Rainier International Discovery Series30,247US$1.87MNo changeJul 31, 2026
Emerging Markets Core Equity 2 Portfolio29,693US$1.83MNo changeJul 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF28,998US$2.47MNewJun 30, 2026
The Emerging Markets Small Cap Series28,027US$1.73M+10,176Jul 31, 2026
All 40 holders
HolderSharesValueChangeAs of
Schwab International Small-Cap Equity ETF25,967US$2.31M−674May 31, 2026
Vanguard Pacific Stock Index Fund13,342US$823K−945Jul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF13,111US$814K+4,843Jul 31, 2026
College Retirement Equities Fund - Total Global Stock Account9,870US$847KNo changeJun 30, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF9,694US$827K+147Jun 30, 2026
Dimensional Emerging Core Equity Market ETF9,626US$598KNo changeJul 31, 2026
Vanguard Total World Stock Index Fund9,622US$594K+1,088Jul 31, 2026
Fidelity Total International Index Fund8,548US$521K+1,163Jul 31, 2026
WisdomTree Emerging Markets SmallCap Dividend Fund6,167US$526K−66Jun 30, 2026
Dimensional Emerging Markets Value ETF5,337US$331KNewJul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF5,026US$312KNo changeJul 31, 2026
Avantis Emerging Markets Equity ETF4,811US$428KNo changeMay 31, 2026
William Blair International Small Cap Growth Fund4,767US$407K−113Jun 30, 2026
WCM Focused Emerging Markets ex China Fund4,507US$387K−55Jun 30, 2026
Emerging Markets Social Core Equity Portfolio3,063US$189KNo changeJul 31, 2026
iShares MSCI Emerging Markets Small-Cap ETF2,908US$259K−456May 31, 2026
Emerging Markets ex China Core Equity Portfolio2,276US$140KNo changeJul 31, 2026
Vanguard ESG International Stock ETF2,257US$201KNo changeMay 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio2,098US$179KNo changeJun 30, 2026
Parametric Tax-Managed Emerging Markets Fund1,947US$167KNo changeJun 30, 2026
Avantis Emerging Markets Small Cap Equity ETF1,500US$133KNo changeMay 31, 2026
World ex U.S. Core Equity Portfolio1,316US$81,183No changeJul 31, 2026
Dimensional Emerging Markets Value Fund683US$42,134NewJul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio662US$40,838No changeJul 31, 2026
TCW White Oak Emerging Markets Equity Fund525US$32,387No changeJul 31, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund499US$30,975+184Jul 31, 2026
Dimensional Emerging Markets ex China Core Equity ETF419US$26,009No changeJul 31, 2026
Dimensional Emerging Markets Sustainability Core 1 ETF281US$17,443No changeJul 31, 2026
State Street(R) SPDR(R) Portfolio MSCI Global Stock Market ETF114US$9,727No changeJun 30, 2026
Avantis Responsible Emerging Markets Equity ETF36US$3,201No changeMay 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about St Pharm Co., Ltd.